Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer

Daniel Eiger, Mariana Brandão, Evandro de Azambuja, Daniel Eiger, Mariana Brandão, Evandro de Azambuja

No abstract available

Keywords: breast cancer; immunotherapy.

Conflict of interest statement

Competing interests: DE: ESMO fellowship (2018–2019) funded by Novartis. MB: travel grant from ROCHEEA: honoraria and advisory board: Roche/GNE; travel grants: Roche/GNE, GSK/Novartis; co-principal investigator of the LORELEI trial (NCT02273973). DE, MB and EdA: research grants for their institute: Roche/GNE, Radius, Astra-Zeneca, Lilly, MSD, Novartis, Synthon, Servier and Pfizer.

References

    1. Schmid P, Rugo HS, Adams S, et al. . Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21:44–59. 10.1016/S1470-2045(19)30689-8
    1. Dalenc F, Bachelot T, Filleron T, et al. . Durvalumab compared to maintenance chemotherapy in patients with metastatic breast cancer: results from phase II randomized trial SAFIR02-IMMUNO. SABCS, 2019.
    1. Gianni L, Huang C-S, Egle D. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. SABCS, 2019.
    1. Schmid P, Park YH, Ferreira M, et al. . KEYNOTE-522: phase 3 study of neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy, followed by adjuvant pembrolizumab versus placebo for early triple-negative breast cancer: pathologic complete response in key subgroups and by treatment. SABCS, 2019.
    1. Gatti-Mays ME, Balko JM, Gameiro SR, et al. . If we build it they will come: targeting the immune response to breast cancer. NPJ Breast Cancer 2019;5:37 10.1038/s41523-019-0133-7
    1. Loi S, Sirtaine N, Piette F, et al. . Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013;31:860–7. 10.1200/JCO.2011.41.0902
    1. Mittendorf EA, Philips AV, Meric-Bernstam F, et al. . PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2014;2:361–70. 10.1158/2326-6066.CIR-13-0127
    1. Luen S, Virassamy B, Savas P, et al. . The genomic landscape of breast cancer and its interaction with host immunity. Breast 2016;29:241–50. 10.1016/j.breast.2016.07.015
    1. Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 2019;19:133–50. 10.1038/s41568-019-0116-x
    1. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature 2017;541:321–30. 10.1038/nature21349
    1. Nanda R, Chow LQM, Dees EC, et al. . Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib keynote-012 study. J Clin Oncol 2016;34:2460–7. 10.1200/JCO.2015.64.8931
    1. Adams S, Schmid P, Rugo HS, et al. . Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol 2019;30:397–404. 10.1093/annonc/mdy517
    1. Adams S, Loi S, Toppmeyer D, et al. . Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol 2019;30:405–11. 10.1093/annonc/mdy518
    1. Emens LA, Cruz C, Eder JP, et al. . Long-Term clinical outcomes and biomarker analyses of Atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol 2019;5:74–82. 10.1001/jamaoncol.2018.4224
    1. Dirix LY, Takacs I, Jerusalem G, et al. . Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b javelin solid tumor study. Breast Cancer Res Treat 2018;167:671–86. 10.1007/s10549-017-4537-5
    1. Cortazar P, Zhang L, Untch M, et al. . Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014;384:164–72. 10.1016/S0140-6736(13)62422-8
    1. Loibl S, Untch M, Burchardi N, et al. . A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol 2019;30:1279–88. 10.1093/annonc/mdz158
    1. Rugo HS, Loi S, Adams S, et al. . Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130. Ann Oncol 2019;30:v858–9. 10.1093/annonc/mdz394.009
    1. Torlakovic E, Lim HJ, Adam J, et al. . "Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. Mod Pathol 2020;33:4–17. 10.1038/s41379-019-0327-4
    1. Carter JM, Polley M-YC, Sinnwell J, et al. . Frequency, characteristics and prognostic factors of PD-L1+ triple negative breast cancer using the PD-L1 SP142 companion assay. SABCS, 2019.
    1. Shindo Y, Hazama S, Tsunedomi R, et al. . Novel biomarkers for personalized cancer immunotherapy. Cancers 2019;11:1223–2. 10.3390/cancers11091223
    1. Fasching PA, Denkert C, Benz S, et al. . Tumor immune-cell activity assessed by RNAseq is an independent predictor of therapy response and prognosis after neoadjuvant chemotherapy in HER2 negative breast cancer patients—An analysis of the GeparSepto trial. SABCS, 2019.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다